Canada markets close in 4 hours

Wesana Health Holdings Inc. (WSNAF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1636+0.0336 (+25.85%)
As of 11:25AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close0.1300
Open0.1370
BidN/A x N/A
AskN/A x N/A
Day's Range0.1370 - 0.1636
52 Week Range0.1100 - 3.9970
Volume36,407
Avg. Volume29,032
Market Cap3.474M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.2710
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    Fresh New Market Movers: Today’s Top Stock Picks for New & Trending Opportunities

    Fresh New Market Movers: Today's Top Stock Picks for New & Trending OpportunitiesVANCOUVER, BC / ACCESSWIRE / June 15, 2022 / Investors want insight. Welcome to the Market Movers Newsletter where we have created a snapshot of new and trending companies that we think investors will want to know about.

  • GlobeNewswire

    Wesana Health CEO Daniel Carcillo to Keynote Charles River Symposium: Re-Imagining Substance Abuse, Addiction, and Mental Health Disorders with Psychedelic Therapies

    His talk will kick-off the daylong biotechnology conference on cutting-edge therapiesCHICAGO and TORONTO, June 08, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, is pleased to confirm CEO Daniel Carcillo will be keynoting the upcoming Charles River Symposium, “Re-imagining Substance Abuse, Addiction, and Me

  • GlobeNewswire

    Wesana Announces First Quarter 2022 Financial Results

    CHICAGO and TORONTO, May 31, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF), a data-driven life sciences company focused on developing the novel therapies of tomorrow and delivering new care paradigms today, has today announced its first quarter 2022 financial results. Q1 2022 Highlights Delivered findings indicating psilocybin potentiates impact of anti-depressantReceived positive feedback from pre-Investigational New Drug (“IND”) meet